Protein Summary
Component of the dystrophin-glycoprotein complex (DGC), a complex that spans the muscle plasma membrane and forms a link between the F-actin cytoskeleton and the extracellular matrix. Preferentially associates with the sarcoglycan subcomplex of the DGC. This gene encodes a member of the dystrophin-glycoprotein complex (DGC). The DGC spans the sarcolemma and is comprised of dystrophin, syntrophin, alpha- and beta-dystroglycans and sarcoglycans. The DGC provides a structural link between the subsarcolemmal cytoskeleton and the extracellular matrix of muscle cells. Two alternatively spliced transcript variants that encode different protein isoforms have been described. [provided by RefSeq, Oct 2008]
- ENST00000242729
- ENSP00000242729
- ENSG00000123096
- ENST00000422622
- ENSP00000396087
- ENST00000540266
- ENSP00000442893
- KRAG
- KRAG
- NSPN
- SPN1
- SPN2
- DAGA5
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
cellular component | 0.72 | ||
kinase perturbation | 0.71 | ||
microRNA | 0.67 | ||
small molecule perturbation | 0.65 | ||
transcription factor perturbation | 0.54 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 97.28 (req: < 5)
Gene RIFs: 14 (req: <= 3)
Antibodies: 60 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 97.28 (req: >= 5)
Gene RIFs: 14 (req: > 3)
Antibodies: 60 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 2
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0